Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VY AADC

Drug Profile

VY AADC

Alternative Names: AAV-AADC; AAV-hAADC; AAV-hAADC-2; AAV-hAADC-gene-therapy - Voyager Therapeutics; AAV2-hAADC; AAV2-hAADC - Voyager Therapeutics; Aromatic-L-amino-acid-decarboxylase-gene-therapy; AV 201; GZ 404477; VY AADC01; VY AADC02

Latest Information Update: 09 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at San Francisco
  • Developer National Institutes of Health (USA); University of California at San Francisco; Voyager Therapeutics
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action Aromatic-L-amino-acid decarboxylase replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 05 May 2019 Efficacy and adverse events data from a phase I trial in Parkinson's disease released by Neurocrine Biosciences and Voyager Therapeutics
  • 29 Jan 2019 Neurocrine Biosciences enter into an option agreement with Voyager Therapeutics to develop and commercialise VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia
  • 07 Jan 2019 Voyager plans a phase III RESTORE-2 trial for Parkinson's disease of similar design and size of RESTORE-1 trial in USA and worldwide in H1 of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top